Organization (Industry)
ANGIODYNAMICS INC
ClinicalTrials.gov lists ANGIODYNAMICS INC as lead sponsor of 24 trials, counting the companies grouped under it. ANGIODYNAMICS INC itself has 4 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 8 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ANGIODYNAMICS INC and 1 company grouped under it: 24 lead-sponsored trials (22 its own, 2 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Eximo Medical Ltd. | 2 | 0 |
Disease areas (26)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atherosclerosis | 4 |
| Pancreatic Neoplasms | 4 |
| Peripheral Arterial Disease | 4 |
| Prostatic Neoplasms | 4 |
| Carcinoma, Hepatocellular | 3 |
Showing 5 of 26 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 3 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Modified FOLFIRINOX Regimen | Pancreatic Neoplasms | Phase 3 | 1 |
| Modified FOLFIRINOX Regimen | Carcinoma, Pancreatic Ductal | Phase 3 | 1 |
| SOC | Pancreatic Neoplasms | Not reported | 1 |
| SOC | Carcinoma, Pancreatic Ductal | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 4 of 4 hit target (n=4) | 0 of 4 on time (n=4) |
Journals published in (37)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of surgical oncology | 4 |
| Hepatology (Baltimore, Md.) | 4 |
| Radiology | 4 |
| Journal of vascular and interventional radiology : JVIR | 3 |
| Pancreas | 3 |
Showing 5 of 37 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 272 | 37 | 2025-12-16 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | 320,174,000 | -36,742,000 | 29,447,000 |
| 2025 | 292,498,000 | -33,993,000 | 26,222,000 |
| 2024 | 303,914,000 | -184,349,000 | 31,512,000 |
| 2023 | 338,752,000 | -52,442,000 | 29,883,000 |
| 2022 | 316,219,000 | -26,547,000 | 30,739,000 |
| 2021 | 291,010,000 | -31,548,000 | 36,390,000 |
| 2020 | 264,157,000 | -166,787,000 | 29,682,000 |
| 2019 | 270,634,000 | 61,340,000 | 28,258,000 |
| 2018 | 261,655,000 | 16,335,000 | 24,338,000 |
| 2017 | 269,788,000 | 5,008,000 | 24,148,000 |
Showing 10 of 12 fiscal years.
Financing and grant events (8)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-05-28 | Debt financing | not disclosed | Sec extracted |
| 2024-03-31 | Royalty / licensing | not disclosed | Sec extracted |
| 2024-03-31 | Other financing | not disclosed | Sec extracted |
| 2023-06-08 | Other financing | not disclosed | Sec extracted |
| 2023-06-08 | Other financing | not disclosed | Sec extracted |
Showing 5 of 8 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 24 |
FDA recalls (178)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Soft-Vu Angiographic Catheter, Pigtail, Non-Braided; SOFT-VU PT 4F X 100CM 035 NB 10SH; Catalog No.: 10707103; Product/UPN No.: H787107071035 (Box), H787107071030 (Pouch); Box Quantity: 10; | Class II | 2026-03-03 |
| Soft -Vu Angiographic Catheter, Kumpe, Non-Braided; SOFT-VU KMP 4F X 40CM 038 NB 0SH; Catalog No.: 10710013; Product/UPN No.: H787107100135 (Box), H787107100130 (Pouch); Box Quantity: 5 pouches; | Class II | 2026-03-03 |
| Soft-Vu Angiographic Catheter, Omni Flush, Non-Braided; SOFT-VU OF 4F X 65CM 038 NB 6SH; Catalog No.: 10714001; Product/UPN No.: H787107140015 (Box), H787107140010 (Pouch); Box Quantity: 10 pouches; | Class II | 2026-03-03 |
| Soft-Vu Angiographic Catheter, Pigtail, Non-Braided; SOFT-VU PT 4F X 65CM 038 NB 10SH; Catalog No.: 10714002; Product/UPN No.: H787107140025 (Box), H787107140020 (Pouch); Box Quantity: 10 pouches; | Class II | 2026-03-03 |
| Soft-Vu Angiographic Catheter, Berenstein, Non-Braided; SOFT-VU BER 4F X 65CM 038 NB 0SH; Catalog No.: 10714009; Product/UPN No.: H787107140095 (Box), H787107140090 (Pouch); Box Quantity: 5 pouches; | Class II | 2026-03-03 |
Showing 5 of 178 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 6 | 2025-12-04 |
Manufacturing and distribution sites (4)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ANGIODYNAMICS, INC. | Queensbury, US | FDA | |
| AngioDynamics, Inc. | Marlborough, US | FDA | |
| ANGIODYNAMICS, INC | Glens Falls, US | FDA | |
| ANGIODYNAMICS, INC | Queensbury, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2026 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2026 | not disclosed | not disclosed |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Moffitt Cancer Center | Co sponsors trial with | 1 |
Latest dated events (523)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 523 events.
Biomarker capability evidence (50)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| C4A | Trial sponsor | Named in trial inclusion criteria |
| C4B; C4B_2 | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial collaborator | Named in trial inclusion criteria |
| CLU | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 50 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, approved assets, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.